Vignettes in osteoporosis: A road map to successful therapeutics

Journal of Bone and Mineral Research

Volumn 19, Issue 1, 2004, Pages 3-10

  Rosen, Clifford J ^a   Black, Dennis M ^b,d,e,f   Greenspan, Susan L ^c,d,g  

^a ST JOSEPH HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Novartis ^*  (Switzerland)

^f NPS Pharmaceuticals

^g ELI LILLY AND COMPANY   (United States)

Author keywords

Anabolics; Antiresorptives; Bone mineral density; Osteoporosis; Risk factors

Indexed keywords

ANABOLIC AGENT; CALCIUM; VITAMIN D; ANTIESTROGEN; BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID; PARATHYROID HORMONE;

DIAGNOSTIC ACCURACY; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL PRACTICE; OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; AGED; ARTICLE; BONE DENSITY; CASE REPORT; CROHN DISEASE; ESTROGEN THERAPY; FEMALE; MALE; METABOLIC BONE DISEASE; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS; VITAMIN D DEFICIENCY;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM; CROHN DISEASE; DIPHOSPHONATES; ESTROGEN ANTAGONISTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 4644341936     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.0301216     Document Type: Review

References (57)

1. 2002 Screening for osteoporosis in postmenopausal women: Recommendations and rationale. Ann Intern Med 137:526-528.
2. Varney LF, Parker RA, Vincelette A, Greenspan SL 1999 Classification of osteoporosis and osteopenia in postmenopausal women is dependent on site-specific analysis. J Clin Densitom 2:275-283.
3. Guyatt GH, Cranney A, Griffith L, Walter S, Krolicki N, Favus M, Rosen C 2002 Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am 31:659-679.
4. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578.
5. Shumaker SA, Legault C, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN III, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J 2003 Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 289:2651-2662.
6. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD 2002 Postmenopausal hormone replacement therapy: Scientific review. JAMA 288:872-881.
7. Nelson HD 2002 Assessing benefits and harms of hormone replacement therapy: Clinical applications. JAMA 288:882-884.
8. Recker RR, Davies KM, Dowd RM, Heaney RP 1999 The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann Intern Med 130:897-904.
9. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR 1995 Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 122:9-16.
10. Delmas PD, Ensrud K, Adachi J, Harper K, Sarkar S, Gennari C, Reginster J, Pols H, Recker RR, Harris SS, Wu W, Genant HK, Black DM, Eastell R 2002 Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609-3617.
11. Rosen CJ, Chesnut CH III, Mallinak NJ 1997 The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 82:1904-1910.
12. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.
13. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N 1994 The diagnosis of osteoporosis. J Bone Miner Res 9:1137-1141.
14. Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C, Delmas P, Eisman J, Johnell O, Jonsson B, Melton L, Oden A, Papapoulos S, Pols H, Rizzoli R, Silman A, Tenenhouse A 2002 A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13:527-536.
15. Kanis JA 1994 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. WHO Study Group. Osteoporos Int 4:368-381.
16. Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D, Luckey M 2002 Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87:4431-4437.
17. Anonymous 1998 Physician's Guide to Prevention and Treatment of Osteoporosis. pp. 1-38.
18. Anonymous 2000 NIH consensus declares osteoporosis a major public health issue. Osteoporos Rep 16:1.
19. Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A 2002 Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:875-883.
20. Black DM, Cummings SR, Karpf DB for the Fracture Intervention Trial Research Group 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541.
21. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352.
22. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340.
23. Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta J, Stakkestad J, Gluer C, Krueger K, Cohen F, Eckert S, Ensrud K, Avioli L, Lips P, Cummings S 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282:637-645.
24. Rackoff PJ, Rosen CJ 1998 Pathogenesis and treatment of glucocorticoid-induced osteoporosis. Drugs Aging 12:477-484.
25. American College of Rheumatology 2001 Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496-1503.
26. Loftus EV Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ III 2002 Long-term fracture risk in patients with Crohn's disease: A population-based study in Olmsted County, Minnesota. Gastroenterology 123:468-475.
27. Klaus J, Armbrecht G, Steinkamp M, Bruckel J, Rieber A, Adler G, Reinshagen M, Felsenberg D, von Tirpitz C 2002 High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 51:654-658.
28. Adler RA, Rosen CJ 1994 Glucocorticoids and osteoporosis. Endocrinol Metab Clin North Am 23:641-654.
29. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA 2000 Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277-285.
30. Papapoulos SE 2000 Bisphosphonates in the treatment of osteoporosis. Principles and efficacy. Ann Med Interne (Paris) 151:504-510.
31. Lukert BP 1995 Etidronate in the management of glucocorticoid-induced osteoporosis. Am J Med 99:233-234.
32. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A 2001 Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202-211.
33. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A 2000 Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610.
34. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627-1633.
35. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 2000 Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial. J Bone Miner Res 15:944-951.
36. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124.
37. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, Blackwell T, Eckert S, Black D 2000 Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 283:1318-1321.
38. Baroud G, Nemes J, Heini P, Steffen T 2003 Load shift of the intervertebral disc after a vertebroplasty: A finite-element study. Eur Spine J 12:421-426.
39. Hodler J, Peck D, Gilula LA 2003 Midterm outcome after vertebroplasty: Predictive value of technical and patient-related factors. Radiology 227:662-668.
40. Peh WC, Gelbart MS, Gilula LA, Peck DD 2003 Percutaneous vertebroplasty: Treatment of painful vertebral compression fractures with intraosseous vacuum phenomena. Am J Roentgenol 180:1411-1417.
41. Tomita S, Kin A, Yazu M, Abe M 2003 Biomechanical evaluation of kyphoplasty and vertebroplasty with calcium phosphate cement in a simulated osteoporotic compression fracture. J Orthop Sci 8:192-197.
42. Watts NB 2003 Is percutaneous vertebral augmentation (vertebroplasty) effective treatment for painful vertebral fractures? Am J Med 114:326-328.
43. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R 2001 Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16:925-931.
44. Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer RM 1998 Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): A randomized controlled trial. JAMA 280:1067-1073.
45. Iida-Klein A, Zhou H, Lu SS, Levine LR, Ducayen-Knowles M, Dempster DW, Nieves J, Lindsay R 2002 Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res 17:808-816.
46. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129-2134.
47. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
48. Neer R, Hayes A, Rao A, Finkelstein J 2002 Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic women. J Bone Miner Res 17:S1;S135.
49. Black D, Greenspan S, Ensrud K, Palermo L, McGowan J, Lang T, Garnero P, Bouxsein M, Bilezikian J, Rosen C 2003 The effects of PTH and alendronate alone or in combination in post-menopausal osteoporosis. N Engl J Med 349:1207-1215.
50. Tinetti ME, Baker DI, McAvay G, Claus EB, Garrett P, Gottschalk M, Koch ML, Trainor K, Horwitz RI 1994 A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 331:821-827.
51. Lips P 2001 Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22:477-501.
52. Trivedi DP, Doll R, Khaw KT 2003 Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial. BMJ 326:469.
53. Lauritzen JB, Petersen MM, Lund B 1993 Effect of external hip protectors on hip fractures. Lancet 341:11-13.
54. Gillespie WJ, Gillespie LD, Handoll HH, Madhok R 2002 The Cochrane Musculoskeletal Injuries Group. Acta Orthop Scand Suppl 73:15-19.
55. Parker M, Gillespie L, Gillespie W, Handoll H, Madhok R, Morton L 2001 Systematic reviews, meta-analyses, and methodology. J Bone Joint Surg Am 83:1433-1435.
56. Black DM, Cooper C 2000 Epidemiology of fractures and assessment of fracture risk. Clin Lab Med 20:439-453.
57. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ III 1992 Incidence of clinically diagnosed vertebral fractures: A population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7:221-227.